Fezagepras

Overview

Fezagepras (Setogepram) acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84 . Fezagepras decreases renal, liver and pancreatic fibrosis. Fezagepras exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions.

Application

Products | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Glucose Metabolism | Products > Signaling Pathways > GPCR/G Protein | Products > Research Areas > Metabolic Disease | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > Free Fatty Acid Receptor | Products > Signaling Pathways > GPR84

Product Information

• Catalog No.: HY-100775A
• CAS No.: 1002101-19-0
• Molecular Formula: C13H18O2
• Molecular Weight: 206.28
• Purity: 99.38%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (12.12 mM); Clear solution
• Availability: In-stock

Source

Original product source